Document is current
Any future updates will be listed below
-
Authors
Syrowatka, Ania https://orcid.org/0000-0002-7161-9770
Kuznetsova, Masha https://orcid.org/0000-0001-6710-526X
Alsubai, Ava
Beckman, Adam L.
Bain, Paul A.
Craig, Kelly Jean Thomas https://orcid.org/0000-0002-9954-2795
Hu, Jianying
Jackson, Gretchen Purcell https://orcid.org/0000-0002-3242-8058
Rhee, Kyu
Bates, David W. https://orcid.org/0000-0001-6268-1540
-
Funding
Funding for this research was provided by:
IBM Watson
- License Information
-
More Information
Article History
Received: 15 October 2020
Accepted: 26 April 2021
First Online: 10 June 2021
Competing interests
: D.W.B. consults for EarlySense, which makes patient safety monitoring systems. He receives cash compensation from CDI (Negev), Ltd, which is a not-for-profit incubator for health IT startups. He receives equity from ValeraHealth which makes software to help patients with chronic diseases. He receives equity from Clew which makes software to support clinical decision-making in intensive care. He receives equity from MDClone which takes clinical data and produces deidentified versions of it. He receives equity from AESOP which makes software to reduce medication error rates. K.J.T.C. and G.P.J. are employed by IBM Watson Health. J.H. is employed by IBM Research. K.R. was employed by IBM Watson Health and is employed by CVS Health. A.L.B. reported receiving consulting fees from Aledade Inc. and was previously employed there. The other co-authors have no disclosures.
